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Zaire ebolavirus (ZEBOV) causes severe hemorrhagic fever in humans and nonhuman primates, with fatality rates in
humans of up to 90%. The molecular basis for the extreme virulence of ZEBOV remains elusive. While adult mice resist
ZEBOV infection, the Mayinga strain of the virus has been adapted to cause lethal infection in these animals. To
understand the pathogenesis underlying the extreme virulence of Ebola virus (EBOV), here we identified the mutations
responsible for the acquisition of the high virulence of the adapted Mayinga strain in mice, by using reverse genetics.
We found that mutations in viral protein 24 and in the nucleoprotein were primarily responsible for the acquisition of
high virulence. Moreover, the role of these proteins in virulence correlated with their ability to evade type I interferon-
stimulated antiviral responses. These findings suggest a critical role for overcoming the interferon-induced antiviral
state in the pathogenicity of EBOV and offer new insights into the pathogenesis of EBOV infection.
Citation: Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, et al. (2006) Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2(7): e73. DOI: 10.1371/
journal.ppat.0020073
Introduction
Zaire ebolavirus (ZEBOV), a member of the family Filoviridae,
genus Ebolavirus, causes severe hemorrhagic fever in humans
andnonhumanprimates(NHPs).Case-fatalityratesforZEBOV
infection in humans are the highest among known viral
hemorrhagic fevers, ranging from 70% to 90% [1–3]. On the
basis of in vitro data, three Ebola virus (EBOV) proteins, the
glycoprotein(GP)[4–6],themembrane-associatedviralprotein
(VP) 24 [7,8], and VP35 [9,10], a component of the replication
complex, are thought to play key roles in EBOV pathogenicity.
The GP, which mediates viral entry, is a major determinant of
viral tropism and may be cytotoxic, although a recent report
has challenged the notion of GP’s cytotoxicity [4–6,11]. VP24
and VP35 are known as type I interferon (IFN) antagonists and
interfere with the type I IFN-mediated antiviral response in
vitro [7,9,10]. However, the role of these proteins in viral
pathogenicity has not been determined in vivo.
Three animal models, NHPs, guinea pigs, and mice, have
been used to study EBOV pathogenesis [12–14]. Generally,
ﬁloviruses do not kill adult immunocompetent rodents,
although some strains have been shown to cause lethal
infections in newborn mice [14]. Bray et al. [14] adapted
ZEBOV to progressively older BALB/c mice and thereby
established a lethal model in adult immunocompetent mice.
Infection of mice with mouse-adapted virus (MA-ZEBOV)
involves primary target cells of the mononuclear phagocytic
system, namely monocytes, macrophages, and dendritic cells,
as well as target organs (spleen, lymph nodes, and liver), as
seen in humans and NHPs, resulting in a disease comparable
to that observed in the latter animals [2,15–17]. Although MA-
ZEBOV–infected mice do not exhibit coagulation abnormal-
ities, a hallmark of EBOV infection in humans and NHPs, this
is understandable given that coagulopathy is not generally
seen in mouse models for acute viral infections [15,18]. Thus,
this mouse model may not exactly mirror all aspects of human
Ebola hemorrhagic fever; however, it does provide a relevant
and convenient animal model with which to study aspects of
pathogenicity and host immune response in vivo [19–21].
The adaptation of ZEBOV to adult mice resulted in a
number of nucleotide changes in both the coding and
noncoding regions (NCRs) of the virus genome [22]. To
identify the molecular features that determine EBOV
virulence in mice, here, we exploited a reverse genetics
system to generate infectious ZEBOV entirely from cloned
cDNA [23] and artiﬁcially generate recombinant viruses
possessing various combinations of wild-type and mouse-
adapted genes. The virulence of these recombinant viruses
was then tested in adult immunocompetent mice.
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Construction and Generation of Recombinant MA-ZEBOV
Mutants from cDNAs
The ZEBOV variant that served as the starting point for
adaptation in mice (referred to as precursor mouse-adapted
virus [pre–MA-ZEBOV]) differed from the published se-
quence of the wild-type ZEBOV (WT-ZEBOV), strain Mayin-
ga, in four nucleotide positions. These mutations may have
been acquired during three consecutive passages in the brains
of newborn mice and/or two passages in Vero E6 cells [14].
Three of these mutations resulted in amino acid changes in
the glycoprotein (GP), while the fourth created a silent
mutation in the open reading frame (ORF) encoding VP40
(Figure 1A and 1B). Serial passage of pre–MA-ZEBOV in
progressively older suckling mice yielded the fully mouse-
adapted variant (MA-ZEBOV), which possessed nine addi-
tional nucleotide changes. Nucleotide substitutions leading to
amino acid changes were found in VP35, VP24, nucleoprotein
(NP) (one amino acid change each), and the polymerase
protein L (two amino acid changes) (Figure 1A and 1B). An
additional two nucleotide changes were found in NCRs
(Figure 1A and 1B), which may affect replication and/or
transcription efﬁciencies. The remaining two nucleotide
modiﬁcations, in the NP and L genes, were silent.
Using a reverse genetics system to create ZEBOV from
plasmid DNAs [23], we generated MA-RG (mouse-adapted
reverse genetics virus) by introducing all but three mutations
into the backbone of WT-ZEBOV (Figure 1B). MA-RG
differed from MA-ZEBOV by the three silent mutations in
the NP, VP40, and L ORFs that were introduced during
adaptation in mice (Figure 1B). We also generated a variety of
recombinant viruses containing various subsets of the
mutations found in MA-ZEBOV (depicted in Figure 2A) to
identify those mutations responsible for mouse adaptation.
The VP24 and NP Genes Determine ZEBOV Virulence in
Mice
To identify the genetic determinants of ZEBOV virulence
in mice, we inoculated groups of BALB/c mice (5 to 6 wk old;
three to six per group) intraperitoneally (i.p.) with 10 focus-
forming units (FFU) of WT-ZEBOV, the original mouse-
adapted virus (MA-ZEBOV), its counterpart generated using
reverse genetics (MA-RG), or viruses containing subsets of the
mutations found in MA-ZEBOV (Figure 2A). This dose (10
FFU) corresponded to 1,000 MLD50 (the amount of virus
required to kill 50% of the mice) for MA-ZEBOV. As
expected, infection of mice with WT-ZEBOV did not produce
a lethal infection or any clinical symptoms, unlike infection
with either MA-ZEBOV or MA-RG. Interestingly, viruses
containing the wild-type NP or VP24 genes in the background
of MA-ZEBOV (MA-NPWT, MA-24WT) did not cause lethal
infection or clinical symptoms in mice, suggesting a critical
role for mutations in these proteins with respect to the
virulence of MA-ZEBOV in mice. In contrast, substitution of
the VP35, GP, and/or L genes of MA-RG with those of WT-
ZEBOV did not dramatically reduce the virulence of the virus
(Figure 2A). Determination of the MLD50, by i.p. inoculation
of mice with 10-fold serial dilutions of viruses, revealed
almost identical MLD50 values for all of these recombinant
viruses with few exceptions (Figure 2A). We, therefore, tested
the inverse genotypes by introducing mouse-adapted NP and
VP24 genes, separately and in combination, into the back-
ground of WT-ZEBOV. Only WT-NP/24MA resulted in a lethal
phenotype; neither of the single gene introductions (WT-
NPMA, WT-24MA) caused disease in mice. These ﬁndings
identiﬁed the speciﬁc amino acid changes in NP and VP24
that are the critical determinants of ZEBOV virulence in
adult mice.
Multiple Mutations in MA-ZEBOV Contribute to Enhanced
Virulence in Mice
All mice infected with virulent viruses displayed the same
clinical symptoms (rufﬂed fur, decreased activity, and weight
loss), but notable differences were observed in the mean time
to death and in the dose ranges that caused morbidity or
mortality (Figure 2B). Infection with MA-ZEBOV resulted in
the shortest mean time to death, with lethal infection induced
by a broad range of inoculum doses (10
5 to 10
3 FFU/mouse).
The artiﬁcially generated MA-RG virus was slightly attenu-
ated, suggesting that the silent mutations in the NP, VP40,
and L genes, by which this mutant differs from MA-ZEBOV,
may make a minor contribution to virulence.
Similarly, the introduction of the mouse-adapted NP and
VP24 genes into the background of WT-ZEBOV (WT-NP/
24MA) did not bestow on WT-ZEBOV the fully pathogenic
phenotype, as demonstrated by a prolonged time to death
and a narrower dose range causing mortality than that of MA-
ZEBOV. Insertion of the mutation into the 59 NCR of the
VP24 gene of WT-NP/24 MA (i.e., WT-NP/24nc/24MA) reduced
the time to death but did not appreciably expand the dose
range for morbidity/mortality, indicating a rather minor
contribution of this mutation to virulence in mice. In
contrast, the nucleotide substitution in the 39 NCR of VP30
c a u s e dam o r ea p p r e c i a b l ee f f e c to nm o u s ev i r u l e n c e
(compare MA-GPWT and MA-GP/30ncWT, which differ only
in the VP30 NCR).
Single gene replacements of the mouse-adapted VP35, GP,
or L with their wild-type counterparts (MA-VP35WT, MA-
GPWT MA-LWT) led to different degrees of attenuation,
indicating that all of the mutations contributed to some
extent to the virulence of MA-ZEBOV in adult mice. Of these
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Synopsis
Zaire ebolavirus causes severe hemorrhagic fever in humans with up
to 90% case-fatality rates. Currently, there are no vaccines or specific
therapeutic interventions available for this devastating viral disease
due, at least in part, to a lack of knowledge regarding the molecular
basis of virulence for this extremely pathogenic agent. While adult
mice resist wild-type Zaire ebolavirus infection, the virus has recently
been adapted to cause lethal infection in mice. In order to
understand the pathogenesis underlying Zaire ebolavirus infection,
the authors identified the mutations responsible for the acquisition
of virulence in mice, using reverse genetics technology, which
allows the generation of genetically altered mutant viruses from
cloned cDNA. By testing the virulence of mutant viruses, two viral
proteins, viral protein 24 and the nucleoprotein, were found to be
primarily responsible for the acquisition of virulence in mice.
Moreover, the role of these proteins in virulence correlated with
their ability to confer resistance to interferon-stimulated antiviral
responses in mouse cells. These findings suggest a critical role of
these proteins in overcoming the interferon-induced antiviral state
in the pathogenicity of Zaire ebolavirus and offer new insights into
the pathogenesis of Zaire ebolavirus infection.mutant viruses, MA-LWT showed the most pronounced
attenuation, indicating that the two amino acid changes in
the L protein of MA-ZEBOV are more critical for virulence in
mice than those in the VP35 or GP proteins.
Growth Characteristics in Mouse Organs
We next compared the growth characteristics of represen-
tative mutant viruses in mice infected with 5 FFU of virus by
examining viral titers in the serum (Figure 3A) and in two
target organs of EBOV, the spleen and liver (Figure 3B and
3C). As expected, WT-ZEBOV replicated poorly in mice,
whereas the virus titers of MA-RG were the highest in all
organs tested, again demonstrating that the full set of
mutations is required to establish the fully pathogenic
phenotype. Efﬁcient virus replication required both the
mouse-adapted NP and VP24 genes (compare WT-NP/24MA
with WT-NPMA and WT-VP24MA), a ﬁnding that correlated
well with virulence, as measured by lethality (Figure 2A and
2B). Likewise, the introduction of either the wild-type NP or
VP24 gene into the background of MA-ZEBOV attenuated
the resulting recombinant viruses (MA-NPWT, MA-24WT),
further emphasizing the critical role of these mutations for
viral replication in mice.
DoMutationsinVP24andNPAffectVirusSensitivitytoIFN?
The suppression of viral multiplication by type I IFN-
mediated antiviral responses has been demonstrated in many
viruses [24], including EBOV [25]. In fact, it is abrogation of
the type I IFN (IFN-a/b) system that makes adult mice
susceptible to EBOV infection [25]. We and others have
identiﬁed EBOV VP24 as being instrumental in this function
(i.e., in inhibiting IFN signaling) [7,26]. To determine whether
the amino acid changes in the VP24 and NP proteins of MA-
ZEBOV facilitate evasion of the type I IFN-induced antiviral
response, we compared virus growth of selected recombinant
viruses in a mouse peritoneal macrophage cell line (RAW
264.7 cells) in the absence or presence of murine IFN-a/b
(Figure 4). WT-ZEBOV grew in nonstimulated cells, albeit to
lower titers compared to the growth of the other viruses
tested (Figure 4A); however, in cells stimulated with IFN at 2 h
Figure 1. Molecular Differences among ZEBOV Mouse-Adapted Variants
(A) Comparison of ZEBOV variants. Pre–MA-ZEBOV differs from wild-type ZEBOV (WT-ZEBOV) by three amino acids in the GP (red triangles) and a silent
mutation in the ORF of the VP40 gene (gray triangle). Serial passage of pre–MA-ZEBOV in progressively older mice yielded MA-ZEBOV [14], which
contains coding changes in the NP, VP35, VP24, and polymerase (L) (all shown in red triangles). Two nucleotide changes localize to the NCRs at the 39
end of the VP30 and the 59 end of the VP24 gene (red triangles); the remaining three modifications in the NP, VP40, and L ORFs are silent (gray
triangles).
(B) Nucleotide and amino acid differences among WT-ZEBOV, pre–MA-ZEBOV, MA-ZEBOV, and MA-RG. The nucleotide changes in GP of pre–MA-ZEBOV,
compared to WT-ZEBOV, as well as the changes acquired during adaptation of pre–MA-ZEBOV in mice are shown in red.
, no change.
DOI: 10.1371/journal.ppat.0020073.g001
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Ebola Virus Virulence in Micepostinfection (Figure 4B) or 12 h prior to and 2 h after
infection (Figure 4C), virus replication was severely reduced.
In contrast, MA-RG grew to much higher titers even in IFN-
stimulated cells, suggesting that its virulence in mice is linked
to its ability to counteract IFN-induced antiviral responses.
This ability clearly correlated with the mutations in the
mouse-adapted VP24 and NP genes. In fact, WT-NP/VP24MA
grew more efﬁciently in IFN-stimulated cells than did MA-
RG, for unknown reasons. In cells that were stimulated with
IFN postinfection, WT-NPMA or WT-VP24MA grew better
than WT-ZEBOV. In contrast, WT-VP24MA, but not WT-
NPMA, failed to replicate efﬁciently in cells treated with IFN
prior to and after infection. These data indicate that the
ability to counteract IFN-induced antiviral responses is
responsible for the high virulence of MA-ZEBOV in this
animal model and that IFN evasion may be critical for EBOV
virulence in other animal models, as well as in humans. In
addition, our ﬁndings show that while both mouse-adapted
VP24 and NP provide the virus with the ability to counteract
the IFN-induced antiviral responses, NP may be more critical
for this effect in vitro. The concerted actions of both
mutations, however, appear necessary for evading IFN-
induced antiviral responses in vivo.
Discussion
In this study, we have identiﬁed molecular determinants of
ZEBOV virulence in mice by using reverse genetics. We found
VP24 and NP to be the primary determinants for adaptation
of WT-ZEBOV in mice and found a correlation between
virulence and the ability of the virus to evade the type I IFN-
induced antiviral response. The ability to overcome the IFN-
Figure 2. Genetic Determinants of Virulence in Adult Mice
(A) Determination of MLD50 values. Bars indicate the genotype of the viral gene: MA-ZEBOV (red), WT-ZEBOV (blue). The MLD50 values of recombinant
viruses were determined by i.p. inoculation of mice (three to six per group) with serial 10-fold dilutions of virus stock and then monitoring of survival
rates. Experiments were carried out in duplicate.
(B) Determination of the mean time to death and dose ranges causing morbidity/mortality. The mean time to death of mice inoculated with 10 FFU
(approximately 1,000 MLD50 for MA-ZEBOV) are indicated. Differences in the mean time to death for mice infected with various mutants, compared to
that of mice infected with MA-ZEBOV, were considered significant when the p-value was ,0.05. The dose range for morbidity/mortality was determined
by inoculating groups of six to nine mice with the indicated amounts of viruses and monitoring the mice for weight loss and time to death. Survival
numbers (dead/total) are color-coded to indicate the severity of infection in infected mice: no disease (black), illness without mortality (green), less than
or equal to 50% mortality (purple), greater than 50% mortality (red). *Dead/total. **p , 0.05.
DOI: 10.1371/journal.ppat.0020073.g002
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pathogenesis of ZEBOV infection in mice and possibly in
humans. Moreover, mutations in other viral proteins and
NCRs also contribute to the virulent phenotype, indicating
that virulence is a multifactor trait.
Recent in vitro studies suggest that VP24 functions as a
type I IFN antagonist [7,26], but the signiﬁcance of this
ﬁnding had not been addressed in vivo until now. Here, we
have demonstrated that single amino acid modiﬁcations in
VP24 and NP of MA-ZEBOV are critical for virus evasion of
IFN-induced antiviral responses. NP has not previously been
considered as a potential IFN antagonist. However, given that
it interacts with VP24 in the formation of nucleocapsids
[27,28], it is not unreasonable to imagine that it may act as an
enhancer and/or stabilizer of VP24 functions. Nevertheless,
since the NP mutation acquired during mouse adaptation of
WT-ZEBOV alone allowed the recombinant virus to replicate
in IFN-treated cells (see Figure 4C), NP likely plays a more
direct role in the evasion of the IFN-induced antiviral
response. Interestingly, WT-NP/VP24MA grew more efﬁciently
than MA-RG in IFN-stimulated cells, in contrast to our in vivo
results. For this reason, it seems likely that the mutations in
VP24 and NP are critical for resistance to IFN-induced
antiviral responses, while the remaining mutations acquired
during adaptation of WT-ZEBOV facilitate efﬁcient virus
replication and/or spread in mice despite their attenuated
phenotype in cell culture systems.
VP35 and GP have previously been linked to EBOV
pathogenicity [4–6,9,10]. VP35 is an IFN antagonist that
interferes with type I IFN synthesis by inhibiting IRF-3
(interferon regulatory factor 3) activation, a necessary step
for the transcription of IFN genes [9,10]. Although the
mutation found in the mouse-adapted VP35 protein was not
responsible for the enhanced virulence of MA-ZEBOV
(Figure 2B), this does not necessarily indicate that VP35-
mediated regulation of IFN levels does not play a part in the
pathogenicity of EBOV. This activity may still be important
for EBOV to achieve high virulence. Likewise, GP is cytotoxic
and is, therefore, thought to contribute to viral pathogenicity
[5,29,30]. However, a recent report suggested that this
cytotoxicity originated from overexpression of GP in cells
[11]. As with VP35, the lack of an adaptive mutation in the GP
of MA-ZEBOV does not necessarily diminish the role of GP in
viral pathogenicity.
Interestingly, the adaptation of ZEBOV in guinea pigs also
resulted in amino acid changes in NP, VP24, and L and in a
nucleotide substitution in the VP30 NCR [8]. Although these
mutations differed in their amino acid positions from those
in MA-ZEBOV, it seems likely that they serve a similar role in
Figure 3. Growth Characteristics of Recombinant Viruses in Mice
Groups of 12 mice were inoculated i.p. with 5 FFU (approximately 500
LD50 values for MA-ZEBOV) of representative viruses. On days 1, 2, 3, and
5 postinoculation, selected organs were removed from three infected
animals per group. Virus titers in serum (A), spleen (B) and liver (C) were
determined in Vero E6 cells by using a focus-forming assay [36].
DOI: 10.1371/journal.ppat.0020073.g003
Figure 4. Effect of Murine Type I IFNs on Recombinant Virus Replication
in Mouse Macrophages
RAW 264.7 cells (mouse peritoneal macrophage-derived cell line) were
infected with a multiplicity of infection of 0.05. Cells were untreated (A),
treated with murine IFN-a/b (500 units/ml) 2 h postinfection (B), or
treated with murine IFN-a/b (500 units/ml) 12 h prior to and again 2 h
after virus adsorption (C). Supernatants were collected on days 0, 1, 2, 3,
and 4 postinfection and titrated by use of a focus-forming unit assay in
Vero E6 cells [36].
DOI: 10.1371/journal.ppat.0020073.g004
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antiviral responses [31,32]. As with mice, additional mutations
(e.g., in L and the VP30 NCR) likely contribute to virulence by
affecting viral transcription/replication.
ThemousemodelusingMA-ZEBOVdoesnotexactlymirror
all aspects of human Ebola hemorrhagic fever [15,18]. Thus,
determinants for virulence of ZEBOV may differ between
mouse and primate models. However, since ZEBOV is
naturally lethal to primates, but not to mice, this model
providedanopportunitytodeciphertherolesofviralproteins
inexpressionofhighvirulenceinahost(i.e.,mice).Ourstudies
showed that ZEBOV VP24 and NP are inadequate for the
expression of high virulence in mice, but upon mutation,
optimally expressed this property. Thus, it is possible that
these viral proteins play an important role in expression of
high virulence in primates. Likewise, the lack of VP35
mutations correlating with pathogenicity in mice is interest-
ing, indicating that ZEBOV VP35 optimally functions in both
primates and mice without additional mutation in an IFN
pathway. Since MA-ZEBOV is attenuated in NHPs [18], one or
more genes into which mutations were introduced during
mouse adaptation of ZEBOV likely play a role in virulence in
primates. Therefore, it will be interesting to examine the
virulence of selected recombinant mouse-adapted variants in
NHPs. Such studies will provide us with valuable information
for understanding ZEBOV pathogenesis in humans.
Of note, we observed resistance in mice to infection with
high infectious doses of MA-ZEBOV (Figure 2B). A similar
ﬁnding has been observed in a mouse model for rabies virus
[33]. The most likely explanation for this ﬁnding is that
inoculation with high doses of virus causes a rapid stimula-
tion of the innate immune response before virus replication
or spread can occur. This topic presents an attractive
research subject that may lead to control measures for EBOV
infections through immunologic modulation of host re-
sponses to viral infection.
In conclusion, the combination of reverse genetics tech-
nology [34] and a small-animal model has allowed us to gain
valuable insights into EBOV pathogenesis. Understanding the
molecular basis of mouse adaptation of ZEBOV will likely
lead to the identiﬁcation of viral genetic determinants of
EBOV virulence and to the elucidation of the roles of speciﬁc
viral proteins in the pathogenic process. A more detailed
molecular understanding of virulence and the host responses
will also be crucial to improving our ability to control EBOV
infections in the future.
Materials and Methods
Cells. Vero E6 (African green monkey kidney) cells, 293T (human
embryonic kidney) cells, and RAW 264.7 cells (mouse peritoneal
macrophages) were grown in DMEM supplemented with 10% FBS, 2
mM L-glutamine, and penicillin (100 U/ml)-streptomycin (100 lg/ml).
Cells were incubated at 37 8Ci n5 %C O 2.
Generation of mutant Ebola viruses. Starting with a cDNA clone
encoding WT-ZEBOV, strain Mayinga [23], we introduced stepwise
mutations to reproduce MA-ZEBOV, using PCR-based mutagenesis.
The resulting plasmids, which are ﬂanked by T7 RNA polymerase
promoter and ribozyme sequences [23], were cotransfected into a
mixed culture of Vero E6 and 293T cells, together with helper
plasmids for the expression of T7 RNA polymerase and EBOV NP,
VP35, VP30, and L (required components of the viral replication
complex), following established protocols [23,35]. All viruses were
ampliﬁed once in Vero E6 cells. DMEM supplemented with 2% FBS
was used to prepare virus stocks.
Virus infectivity titers (FFU) were obtained by counting the
number of infected cell foci detected by use of an indirect
immunoﬂuorescent antibody assay, as previously described [36].
EBOV antigen-positive foci were detected with a rabbit polyclonal
anti-VP40 antibody and a goat anti-rabbit IgG-FITC conjugate [37].
Animal experiments. Five- to 6-wk-old female BALB/c mice were
obtained from a commercial supplier (Charles River Laboratories,
Wilmington, Massachusetts, United States). All mice were housed in
microisolator cages and allowed to acclimatize for 5 days prior to use
in experiments.
To assay virulence, groups of three to six mice were each
inoculated i.p. at two different sites with 10 FFU of virus in 0.1 ml
of DMEM. Following infection, mice were observed daily for clinical
symptoms and their weights were recorded for 11 d postinoculation.
All surviving animals were observed for at least 21 d (three times the
average duration of survival of the control animals).
The MLD50 was determined by i.p. inoculation of mice (three to six
per group) with serial 10-fold dilutions of virus and monitoring of the
survival rates.
To assess virus growth characteristics in mice, groups of 12 animals
were inoculated i.p. with 5 FFU of virus (corresponds to approx-
imately 500 MLD50 f o rM A - Z E B O V ) .O nd a y s1 ,2 ,3 ,a n d5
postinfection, spleen, liver, and blood were collected from three
infected mice, and the spleen and liver samples were homogenized.
Viral infectivity titers were determined by use of a focus-forming
assay in Vero E6 cells [36].
All work with live EBOV was performed in the BSL-4 laboratory of
the National Microbiology Laboratory of the Public Health Agency of
Canada. All animal experiments were performed in accordance with
approved animal use documents and according to the guidelines of
the Canadian Council on Animal Care.
Replication kinetics in IFN-stimulated murine cells. RAW 264.7
cells were infected with the respective viruses at a multiplicity of
infection of 0.05. The cells were either left untreated or treated with
500 units/ml murine IFN-a/b 2 h postinfection, or 12 h prior to
infection and again 2 h postinfection. For all samples, virus titers in
the supernatants were determined on days 0, 1, 2, 3, and 4
postinfection by use of the focus-forming assay in Vero E6 cells
[36]. The ﬁrst sample (day 0) was collected after the virus had
adsorbed and the cell monolayer had been washed three times.
Statistical analyses. All virus titers in the growth kinetics experi-
ments are shown as the mean 6 SEM. The p-values in Figure 2B were
calculated by using the Student’s t-test (two-tailed distribution, two-




The GenBank accession numbers for the genes mentioned in this
paper are WT-ZEBOV, strain Mayinga (AF086833) and MA-ZEBOV
variant (AF499101).
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